VICL Slumps, FDA Greenlights SRPT's DMD Drug, Domino Effect On PTCT

Shares of Vical Inc. (VICL) slumped more than 22% on Monday as its phase II study of investigational cytomegalovirus vaccine ASP0113 in kidney transplant patients failed to meet the primary endpoint.

from RTT - Biotech http://ift.tt/2d7r2FX
via IFTTT